Session IV: Novel Targets
Novel Targets
The central theme for session IV at the Myeloma2018 meeting was novel drug targets for MM targets. Nizar Bahlis, MD, and Enrique Ocio, MD, PhD, identify MCL-1 as a possible target in MM, indicating a potential niche for MCL-1 inhibitors. Leif Bergsagel, MD, Robert Orlowski, MD, PhD, and Keith Stewart, MBChB, explore further drug targets.
